Feature | April 27, 2015

New Concept of Heart Disease Posits Vitamin C Deficiency as Culprit

Study of transgenic mouse model shows chronic vitamin C deficiency leads to structural weakness of blood vessel walls, causing atherosclerotic development

April 27, 2015 — Scientific confirmation has just been published in the American Journal of Cardiovascular Disease that atherosclerosis, the underlying process of heart attacks and strokes, is generally not caused by high cholesterol blood levels. It is rather the result of a structural weakness of the blood vessel walls caused by chronic deficiency of ascorbate (vitamin C).

Heart attacks, strokes and other forms of cardiovascular disease are the single largest disease on our planet with more than 17 million deaths each year. The continuation of this disease in epidemic proportions proves that its true nature has not yet been sufficiently understood. Moreover, the current hypothesis that high cholesterol levels in blood triggers cardiovascular disease cannot answer the most basic question of cardiology: Cholesterol has the same concentration in both arteries and veins. So why do atherosclerotic plaques occur only in arteries – but not in veins? Moreover, why do they develop almost always in the few inches of coronary arteries – but rarely in other organs? Or why is atherosclerosis, a hallmark of the human race, basically unknown in animal species? 

Researchers from the Dr. Rath Research Institute in California developed a unique animal model. It is a transgenic mouse that resembles human metabolism in its key aspects, the inability to produce vitamin C and, at the same time, the synthesis of human Lipoprotein(a) – a variant of low-density-lipoprotein (LDL).  Using this animal model they demonstrated that atherosclerosis, generally, starts with a dietary depletion of vitamin C and the ensuing structural weakness of the artery walls. This metabolic condition results in an increase in serum Lipoprotein(a) levels and its accumulation in the vascular wall that parallels atherosclerotic lesion development.

This study confirms the scientific concept published in 1990 in the 'Proceedings of the National Academy of Sciences, USA' by Matthias Rath, M.D., together with two-time Nobel Prize winner Linus Pauling, M.D. They proposed that Lipoprotein(a) is a repair molecule that functions as a surrogate for vitamin C in the impaired vascular wall. 

The most fascinating aspect of this animal model is the fact that it reproduces a genetic switch, the disappearance of vitamin C to the appearance of Lipoprotein(a), from about 40 million years ago. It proves the concept that a distinct event during the evolution of man can explain the susceptibility of modern man to cardiovascular disease.

For more information: www.ajcd.us


Related Content

Feature | Cath Lab | Kyle Hardner

Since receiving FDA approval in 2016, intravascular lithotripsy (IVL) systems have grown in popularity among ...

Home November 14, 2025
Home
News | Cath Lab

Nov. 11, 2025 — FastWave Medical has successfully completed enrollment in its 30-patient coronary feasibility study and ...

Home November 13, 2025
Home
News | Cath Lab

Oct. 28, 2025 — Results from the first-of-its-kind randomized PROCTOR trial found that a strategy of saphenous vein ...

Home November 04, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Results from the PREVUE-VALVE study suggest that there are currently at least 4.7 million people aged 65 ...

Home October 29, 2025
Home
News | Cath Lab

Oct. 25, 2025 — Medtronic plc has announced the launch of the Stedi Extra Support guidewire, designed to enhance ...

Home October 28, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Elixir Medical, a developer of technologies to treat cardiovascular disease, has announced new clinical ...

Home October 28, 2025
Home
News | Cath Lab

Oct. 22, 2025 — Heartflow, Inc. has introduced Heartflow PCI Navigator, the newest addition to the Heartflow One ...

Home October 23, 2025
Home
News | Cath Lab

Oct. 15, 2025 — Stereotaxis recently announced it has obtained CE Mark in Europe and submitted a 510(k) application to ...

Home October 16, 2025
Home
News | Cath Lab

Oct. 7, 2025 — Medtronic has announced the full distribution of the Neuroguard IEP System (Neuroguard) after a ...

Home October 07, 2025
Home
News | Cath Lab

Sept. 22, 2025 — Nicklaus Children's Heart Institute in Miami, Florida, is now offering bedside transcatheter patent ...

Home September 23, 2025
Home
Subscribe Now